Microarray-based Obesity Target Screening Service
InquiryObesity is a multi-faceted metabolic disorder characterized by chronic inflammation, endocrine disruption, and altered lipid metabolism. Identifying high-affinity therapeutic targets and predictive biomarkers is critical for the development of next-generation anti-obesity agents. Protheragen provides a specialized microarray-based obesity target screening service designed to accelerate preclinical drug discovery.
Advanced Microarray Solutions for Adipokine and Metabolic Target Mapping
By leveraging high-density protein and antibody microarrays, we enable researchers to perform high-throughput screening of metabolic regulators, adipokines, and signaling molecules. Our platform transitions research from broad-spectrum observation to precise molecular interaction analysis, facilitating the identification of novel GPCR targets, enzyme inhibitors, and hormonal modulators.
Core Technologies
Protheragen utilizes a suite of advanced microarray platforms specifically engineered to deconstruct the molecular complexities of metabolic disease. Our point-by-point technological framework includes:
Our proprietary antibody arrays allow for the concurrent detection of hundreds of obesity-related cytokines, adipokines, and inflammatory markers from a single preclinical sample. This provides a "system-wide" view of the endocrine environment, identifying subtle shifts in protein expression that single-target assays like ELISA frequently overlook.
We deploy high-throughput protein chips containing thousands of purified, natively folded human proteins. This technology is essential for target identification and off-target screening, allowing researchers to observe direct physical interactions between a drug candidate and the proteome to ensure high therapeutic specificity.
To address the developmental and environmental roots of obesity, we offer specialized arrays that map DNA methylation patterns. This enables the study of how gene expression in adipocytes is silenced or activated during different stages of metabolic dysfunction.
For projects focusing on hormonal signaling and enzyme kinetics, our peptide arrays facilitate the mapping of binding epitopes and phosphorylation sites. This is a critical tool for identifying the specific amino acid sequences responsible for metabolic receptor activation.
Utilizing high-resolution laser scanning, we quantify molecular interactions with a wide dynamic range and high signal-to-noise ratio. This raw data is then processed through our specialized bioinformatics pipeline to provide pathway enrichment, clustering, and metabolic network mapping.
Solution Scope
The Protheragen microarray-based obesity target screening service covers an extensive range of biological targets and metabolic indicators:
- Adipokine & Cytokine Profiling
Screening for leptin, adiponectin, ghrelin, and inflammatory markers (IL-6, TNF-alpha) to evaluate the metabolic state of preclinical models.
- Hormonal Regulator Mapping
Identifying changes in insulin-like growth factors and thyroid-stimulating hormones within complex biological matrices.
- Off-Target Interaction Screening
Assessing the specificity of lead compounds by screening them against a vast library of non-target proteins to minimize future safety risks.
Analyzing DNA methylation patterns in adipose-derived stem cells to understand the programming of obesity.
- Lipid Metabolism Enzyme Screening
Evaluating the interaction of candidates with key enzymes involved in fatty acid synthesis and oxidation.
Consult with our Specialists to Customize Your Screening Panel
Workflow
Our streamlined workflow ensures rigorous data generation and reproducible results for every preclinical project:
Fields of Application
Our screening services are essential for various stages of preclinical development:
- Target Identification: Discovering novel receptors or enzymes that drive adipose tissue expansion or insulin resistance.
- Lead Optimization: Assessing the binding affinity and selectivity of small molecules or monoclonal antibodies.
- Mechanism of Action (MoA) Studies: Elucidating the downstream signaling pathways activated or inhibited by a therapeutic candidate.
- Safety Toxicology: Early-stage screening for potential off-target effects in metabolic tissues to reduce attrition rates.
- Biomarker Development: Identifying a signature of proteins that correlate with drug efficacy in animal models.
Advantages
Protheragen stands at the forefront of metabolic screening through several key differentiators:
High Sensitivity
Our platforms detect picogram levels of protein, enabling the identification of rare biomarkers that traditional ELISA methods might miss.
Minimal Sample Volume
Achieve comprehensive data from as little as 10–50 µL of sample, preserving precious preclinical materials.
Verified Specificity
We utilize rigorous validation protocols to ensure minimal cross-reactivity, providing high-confidence data for lead selection.
Rapid Turnaround
Our automated processing environment delivers full bioinformatic reports significantly faster than conventional proteomics workflows.
Explore how our high-precision screening elevates your drug discovery pipeline.
Customer Review
Strategic Insights for Lead Optimization
"The team at Protheragen provided us with a level of insight we couldn't achieve with standard assays. Their microarray platform identified three novel cytokine interactions in our high-fat diet model that have since become central to our lead optimization program. The bioinformatic package was exceptionally clear, allowing us to move directly into validation studies. We look forward to utilizing their epigenetic screening services in our next phase."
Dr. P. S., Senior Director of Metabolic Research
Streamlining Discovery and Risk Mitigation
"Working with Protheragen streamlined our target discovery process significantly. Their ability to screen for off-target binding early in the preclinical stage saved us months of potential rework. The technical support was responsive and deeply knowledgeable about the nuances of obesity biomarkers. We plan to integrate their screening services into all our upcoming metabolic disease programs."
Dr. R. A., Drug Discovery Division
Frequently Asked Questions
-
How does microarray screening compare to traditional ELISA for obesity research?
Microarrays allow for the simultaneous analysis of hundreds of targets, whereas ELISA is typically limited to one. This multiplexing capability provides a systemic view of the metabolic environment, saving time and sample volume.
-
Can you detect low-abundance adipokines in serum samples?
Yes, our high-sensitivity antibody arrays are specifically designed to capture low-abundance signaling proteins that are critical in metabolic regulation.
-
What types of preclinical samples are compatible with your service?
We routinely process serum, plasma, cell culture supernatants, and various tissue lysates, including white and brown adipose tissue.
-
How do you ensure the reproducibility of the screening results?
Every array includes internal controls and replicates. We also follow strict SOPs for sample handling and signal normalization to ensure inter-assay consistency.
-
Is it possible to customize the array to include specific targets of interest?
Absolutely. We offer customizable panels where specific antibodies or proteins can be spotted to meet your unique research requirements.
-
What kind of bioinformatic support do you provide?
Our reports include heat maps, fold-change analysis, pathway enrichment (KEGG/reactome), and protein-protein interaction networking.
-
Can this service help in identifying off-target effects of my drug candidate?
Yes, our protein microarrays can screen your lead compound against thousands of human proteins to identify unintended binding, helping to predict potential side effects.
-
How much sample volume is required for a standard screening?
Generally, we require less than 50 microliters of sample per array, making it ideal for studies involving small animal models.
-
What is the typical turnaround time for a project?
Standard projects are usually completed within 3 to 5 weeks from the receipt of samples to the delivery of the final bioinformatic report.
Contact Us
Protheragen is committed to delivering high-quality, actionable data to advance your obesity research. Our expert team is ready to assist you in designing a screening strategy that meets your specific preclinical objectives. Welcome to Contact Protheragen and start communication.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.